ALEHT Share Price

Open 0.30 Change Price %
High 0.30 1 Day 0.00 0.00
Low 0.28 1 Week 0.02 7.41
Close 0.29 1 Month -0.01 -3.33
Volume 217040 1 Year -0.18 -38.30
52 Week High 0.55
52 Week Low 0.25
ALEHT Important Levels
Resistance 2 0.31
Resistance 1 0.30
Pivot 0.29
Support 1 0.28
Support 2 0.27
EPA France Most Active Stocks
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
ALALO 0.04 33.33%
ACA 10.84 2.26%
More..
EPA France Top Gainers Stocks
ALALO 0.04 33.33%
ALFRE 1.20 18.81%
APAM 33.78 15.72%
APAM 33.78 15.72%
MLLOI 3.80 15.15%
DEXB 17.47 13.89%
DEXB 17.47 13.89%
ALVER 1.10 13.40%
MT 4.53 12.97%
MT 4.53 12.97%
More..
EPA France Top Losers Stocks
VRNL 0.59 -26.25%
CIB 0.08 -11.11%
CIB 0.08 -11.11%
CIB 0.08 -11.11%
CIB 0.08 -11.11%
ALMAS 0.81 -10.00%
ALMGI 1.45 -9.38%
THER 32.00 -8.23%
THER 32.00 -8.23%
EPCP 650.00 -7.14%
More..

Diaxonhit (EPA: ALEHT)

ALEHT Technical Analysis 4
As on 5th Dec 2016 ALEHT Share Price closed @ 0.29 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.39 & Sell for SHORT-TERM with Stoploss of 0.32 we also expect STOCK to react on Following IMPORTANT LEVELS.
ALEHT Target for December
1st Target up-side 0.39
2nd Target up-side 0.43
3rd Target up-side 0.47
1st Target down-side 0.27
2nd Target down-side 0.23
3rd Target down-side 0.19
ALEHT Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.exonhit.com
ALEHT Address
ALEHT
65 Boulevard Mass
Paris, 75013
France
Phone: 33 1 53 94 77 00
Fax: 33 1 53 94 77 07
ALEHT Latest News
Diaxonhit H1 net loss widens to 3.9 million euros   Reuters Key Development   - 21st Sep 16
Diaxonhit H1 consolidated revenues decrease to 15.0 million euros   Reuters Key Development   - 21st Jul 16
CareDx Announces Agreement to Purchase 78 Percent of the Outstanding Shares of ...   GlobeNewswire (press release)   - 16th Dec 15
France Biotech Announces the Second Edition of "French Life Science Days" New York   GlobeNewswire (press release)   - 10th Jun 15
Diaxonhit Grants Felicitex a Global Exclusive License of a Series of Lead ...   GlobeNewswire (press release)   - 19th May 15
Next Generation Cancer Diagnostics: Technologies and Global Markets   PR Newswire (press release)   - 04th Sep 14
Companion Diagnostics: Technologies and Markets   PR Newswire (press release)   - 03rd Sep 14
The World Market for Infectious Disease Diagnostic Tests   PR Newswire (press release)   - 19th May 14
The World Market for Immunoassays   PR Newswire (press release)   - 24th Apr 14
Global Biochip Markets: Microarrays and Lab-on-a-Chip   PR Newswire (press release)   - 08th Nov 13
Interactive Technical Analysis Chart Diaxonhit ( ALEHT EPA France )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Diaxonhit
ALEHT Business Profile
Diaxonhit is engaged in the discovery and commercialization of in-vitro diagnostic products in transplantation, infectious diseases, and cancer diagnosis specialty areas. It markets a proprietary test, Tetanus Quick Stick, used in emergency clinics for the evaluation of the protective status of a patient against tetanus. The company's in-house development products include the BJI InoPlex kit, a test that allows the detection of infections linked to articular prosthesis; and EHT Dx15, a test for the diagnosis of thyroid cancer, as well as licensed product comprises AlloMap, a gene-expression profiling based blood test for regular and non-invasive surveillance of heart transplant recipients for acute cellular rejection. It is also developing companion diagnostics for resistant and breast cancers; and tests to monitor the direct effect of drug activity. The company was formerly known as Exonhit S.A. and changed its name to Diaxonhit in December 2012. Diaxonhit was founded in 1997 and is headquartered in Paris, France.